Combination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast cancer models

W. Guo, H. Zhu, L. Zhang, J. Davis, Fuminori Teranishi, J. A. Roth, C. Stephens, J. Fueyo, H. Jiang, C. Conrad, B. Fang

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy and oncolytic adenovirotherapy have been investigated extensively in xenografic human tumor models established in immunocompromised nude mice. However, the effects of these therapies on syngeneic murine tumors in immunocompetent settings were not well documented. We hypothesized that TRAIL gene therapy used with an oncolytic adenovirus would overcome the weaknesses of the two therapies used individually. In this study, we evaluated the antitumor effects of an oncolytic adenovirus, Delta24, in both human and murine breast cancer cell lines. We also analyzed the effects of TRAIL gene therapy combined with oncolytic virotherapy in these cancer cells. Our results showed that Delta24 can replicate and help the E1-deleted adenovector replicate in murine cancer cells. We also found that these two therapies combined had greater antitumor activity than either one alone in both human and murine breast cancer cells lines and in the syngeneic breast cancer models established in immunocompetent mice. Moreover, Delta24 virotherapy alone and combined with TRAIL gene therapy dramatically reduced the spontaneous liver metastasis that originated in the subcutaneous 4T1 tumor established in Balb/c mice. These findings provide important considerations in the development and preclinical assessments of oncolytic virotherapy.

Original languageEnglish
Pages (from-to)82-90
Number of pages9
JournalCancer Gene Therapy
Volume13
Issue number1
DOIs
Publication statusPublished - Jan 1 2006
Externally publishedYes

Fingerprint

Genetic Therapy
Breast Neoplasms
Oncolytic Virotherapy
Neoplasms
Adenoviridae
Cell Line
Nude Mice
Therapeutics
Tumor Necrosis Factor-alpha
Apoptosis
Neoplasm Metastasis
Ligands
Liver

Keywords

  • Liver metastasis
  • Murine tumor model
  • Synergism
  • TRAIL
  • Virotherapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Cancer Research

Cite this

Combination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast cancer models. / Guo, W.; Zhu, H.; Zhang, L.; Davis, J.; Teranishi, Fuminori; Roth, J. A.; Stephens, C.; Fueyo, J.; Jiang, H.; Conrad, C.; Fang, B.

In: Cancer Gene Therapy, Vol. 13, No. 1, 01.01.2006, p. 82-90.

Research output: Contribution to journalArticle

Guo, W, Zhu, H, Zhang, L, Davis, J, Teranishi, F, Roth, JA, Stephens, C, Fueyo, J, Jiang, H, Conrad, C & Fang, B 2006, 'Combination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast cancer models', Cancer Gene Therapy, vol. 13, no. 1, pp. 82-90. https://doi.org/10.1038/sj.cgt.7700863
Guo, W. ; Zhu, H. ; Zhang, L. ; Davis, J. ; Teranishi, Fuminori ; Roth, J. A. ; Stephens, C. ; Fueyo, J. ; Jiang, H. ; Conrad, C. ; Fang, B. / Combination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast cancer models. In: Cancer Gene Therapy. 2006 ; Vol. 13, No. 1. pp. 82-90.
@article{a0d9399a0a2e46b49330a66413aecd8f,
title = "Combination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast cancer models",
abstract = "Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy and oncolytic adenovirotherapy have been investigated extensively in xenografic human tumor models established in immunocompromised nude mice. However, the effects of these therapies on syngeneic murine tumors in immunocompetent settings were not well documented. We hypothesized that TRAIL gene therapy used with an oncolytic adenovirus would overcome the weaknesses of the two therapies used individually. In this study, we evaluated the antitumor effects of an oncolytic adenovirus, Delta24, in both human and murine breast cancer cell lines. We also analyzed the effects of TRAIL gene therapy combined with oncolytic virotherapy in these cancer cells. Our results showed that Delta24 can replicate and help the E1-deleted adenovector replicate in murine cancer cells. We also found that these two therapies combined had greater antitumor activity than either one alone in both human and murine breast cancer cells lines and in the syngeneic breast cancer models established in immunocompetent mice. Moreover, Delta24 virotherapy alone and combined with TRAIL gene therapy dramatically reduced the spontaneous liver metastasis that originated in the subcutaneous 4T1 tumor established in Balb/c mice. These findings provide important considerations in the development and preclinical assessments of oncolytic virotherapy.",
keywords = "Liver metastasis, Murine tumor model, Synergism, TRAIL, Virotherapy",
author = "W. Guo and H. Zhu and L. Zhang and J. Davis and Fuminori Teranishi and Roth, {J. A.} and C. Stephens and J. Fueyo and H. Jiang and C. Conrad and B. Fang",
year = "2006",
month = "1",
day = "1",
doi = "10.1038/sj.cgt.7700863",
language = "English",
volume = "13",
pages = "82--90",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Combination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast cancer models

AU - Guo, W.

AU - Zhu, H.

AU - Zhang, L.

AU - Davis, J.

AU - Teranishi, Fuminori

AU - Roth, J. A.

AU - Stephens, C.

AU - Fueyo, J.

AU - Jiang, H.

AU - Conrad, C.

AU - Fang, B.

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy and oncolytic adenovirotherapy have been investigated extensively in xenografic human tumor models established in immunocompromised nude mice. However, the effects of these therapies on syngeneic murine tumors in immunocompetent settings were not well documented. We hypothesized that TRAIL gene therapy used with an oncolytic adenovirus would overcome the weaknesses of the two therapies used individually. In this study, we evaluated the antitumor effects of an oncolytic adenovirus, Delta24, in both human and murine breast cancer cell lines. We also analyzed the effects of TRAIL gene therapy combined with oncolytic virotherapy in these cancer cells. Our results showed that Delta24 can replicate and help the E1-deleted adenovector replicate in murine cancer cells. We also found that these two therapies combined had greater antitumor activity than either one alone in both human and murine breast cancer cells lines and in the syngeneic breast cancer models established in immunocompetent mice. Moreover, Delta24 virotherapy alone and combined with TRAIL gene therapy dramatically reduced the spontaneous liver metastasis that originated in the subcutaneous 4T1 tumor established in Balb/c mice. These findings provide important considerations in the development and preclinical assessments of oncolytic virotherapy.

AB - Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy and oncolytic adenovirotherapy have been investigated extensively in xenografic human tumor models established in immunocompromised nude mice. However, the effects of these therapies on syngeneic murine tumors in immunocompetent settings were not well documented. We hypothesized that TRAIL gene therapy used with an oncolytic adenovirus would overcome the weaknesses of the two therapies used individually. In this study, we evaluated the antitumor effects of an oncolytic adenovirus, Delta24, in both human and murine breast cancer cell lines. We also analyzed the effects of TRAIL gene therapy combined with oncolytic virotherapy in these cancer cells. Our results showed that Delta24 can replicate and help the E1-deleted adenovector replicate in murine cancer cells. We also found that these two therapies combined had greater antitumor activity than either one alone in both human and murine breast cancer cells lines and in the syngeneic breast cancer models established in immunocompetent mice. Moreover, Delta24 virotherapy alone and combined with TRAIL gene therapy dramatically reduced the spontaneous liver metastasis that originated in the subcutaneous 4T1 tumor established in Balb/c mice. These findings provide important considerations in the development and preclinical assessments of oncolytic virotherapy.

KW - Liver metastasis

KW - Murine tumor model

KW - Synergism

KW - TRAIL

KW - Virotherapy

UR - http://www.scopus.com/inward/record.url?scp=29144453389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29144453389&partnerID=8YFLogxK

U2 - 10.1038/sj.cgt.7700863

DO - 10.1038/sj.cgt.7700863

M3 - Article

C2 - 16037823

AN - SCOPUS:29144453389

VL - 13

SP - 82

EP - 90

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 1

ER -